Ⅳ期非小细胞肺癌伴驱动基因改动的治疗:ASCO动态指南2022.3版
该ASCO动态指南针对Ⅳ期非小细胞肺癌伴驱动基因改动的治疗,由常设专家小组持续系统审查文献并定期更新,2022.3版提供了该领域的治疗推荐。指南强调需结合独立专业判断,并说明不适用于替代个体化决策。
要点
- ASCO动态指南针对Ⅳ期非小细胞肺癌伴驱动基因改动的治疗定期更新。
- 由常设专家小组持续系统审查健康文献并遵循ASCO指南方法学手册。
- 动态指南及更新不替代治疗提供者的独立专业判断。
核心结论
- ASCO动态指南针对Ⅳ期非小细胞肺癌伴驱动基因改动的治疗提供定期更新的推荐,2022.3版已发布。
研究设计与样本
- 由常设专家小组按ASCO指南方法学手册持续系统审查健康文献并定期更新。
临床怎么用
- 动态指南及更新不替代治疗提供者的独立专业判断,也不涵盖患者间的个体差异。
- 更新定期发布,可在 https://ascopubs.org/nsclc-da-living-guideline 获取。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis; as described in the ASCO Guidelines Methodology Manual. ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines. Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating provider and do not account for individual variation among patients. See appendix for disclaimers and other important information (Appendix 1 and Appendix 2). Updates are published regularly and can be found at https://ascopubs.org/nsclc-da-living-guideline.
引用
- Jaiyesimi IA, Owen DH, Ismaila N, et al. Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.3. J Clin Oncol. 2023. PMID: 36802359. doi:10.1200/JCO.22.02782
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。